Nalaganje...
Naltrexone extended-release injection: an option for the management of opioid abuse
The United States Food and Drug Administration (FDA) approved naltrexone, a synthetic competitive antagonist at opioid receptors, in oral form in 1984 for use in the management of opioid abuse and addiction. Because naltrexone and its major metabolite, 6-β-naltrexone, are both competitive antagonist...
Shranjeno v:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2011
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3846318/ https://ncbi.nlm.nih.gov/pubmed/24474859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/SAR.S17920 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|